Antidepressant Treatment Strategies in Major Depressive Disorder

Major Depressive Disorder (MDD) is a leading cause of global disability, and pharmacological intervention remains a cornerstone of its management. First-line agents typically comprise selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline reuptake inhibitors (SNRIs), owing to their favourable balance of efficacy and tolerability. When initial treatment fails to achieve remission, clinicians may pursue dose optimisation, switching to an alternative class such as tricyclic antidepressants or monoamine oxidase inhibitors, or employ augmentation strategies with adjunctive agents (for example lithium or atypical antipsychotics). In treatment-resistant cases, somatic therapies including electroconvulsive therapy and newer brain-stimulation techniques offer rapid relief for severe or suicidal presentations. Increasing emphasis on individualised care has driven investigations into biomarkers of treatment response—ranging from peripheral serotonin levels to pharmacogenetic profiles—to inform precision prescribing. Beyond medication, combined approaches that integrate psychotherapy and lifestyle interventions are essential for long-term recovery and relapse prevention. A sequential, measurement-based paradigm—monitoring early symptom change and adapting strategy at predefined intervals—has gained traction as a means to shorten time to remission and reduce chronicity.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antidepressant Treatment Strategies in Major Depressive Disorder publication trend

The graph below shows the total number of articles in antidepressant treatment strategies in major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Selective Serotonin Reuptake Inhibitors (SSRIs): A class of antidepressants that increase synaptic serotonin by blocking its reabsorption into presynaptic neurons.

Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs): Antidepressants that inhibit the reuptake of both serotonin and noradrenaline, enhancing mood regulation pathways.

Treatment-Resistant Depression (TRD): A state in which a patient fails to respond adequately to two or more adequate antidepressant trials.

Augmentation: The addition of a secondary agent (such as lithium, antipsychotics or stimulating medications) to enhance antidepressant efficacy when monotherapy is insufficient.

Biomarker: A measurable biological indicator—such as blood serotonin level or genetic variant—that may predict treatment response or guide personalised therapy.

Pharmacogenetics: The study of how genetic variation influences individual responses to medications, with the aim of optimising drug selection and dosing.

References

1. Routine treatment pathways in a cohort of patients with major depression and suicidality in Italy: the ARIANNA observational study. Comprehensive Psychiatry (2023).
2. Peripheral serotonin levels as a predictor of antidepressant treatment response: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024).
3. Genetic determinants of antidepressant and antipsychotic drug response. European Archives of Psychiatry and Clinical Neuroscience (2024).